Acurx Pharmaceuticals (ACXP) EBIT (2024 - 2026)

Acurx Pharmaceuticals (ACXP) has reported EBIT for 3 consecutive years, with -$2.3 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, EBIT fell 1.65% year-over-year to -$2.3 million; the trailing twelve-month figure through Jun 2026 stood at -$7.7 million (up 23.82% YoY), and the FY2025 full-year result was -$8.1 million, up 42.7% from the prior year.
• EBIT retreated to -$2.3 million in Q2 2026 per ACXP's latest filing, from -$1.7 million in the prior quarter.
• Across five years, EBIT topped out at -$1.6 million in Q4 2025 and bottomed at -$4.1 million in Q2 2024.
• Historically, EBIT has averaged -$2.4 million across 3 years, with a median of -$2.3 million in 2025.
• The sharpest annual moves came in 2025 and 2026: EBIT soared 44.95% in 2025, then fell 1.65% in 2026.
• Over 3 years, EBIT stood at -$2.8 million in 2024, then jumped by 42.12% to -$1.6 million in 2025, then slumped by 42.68% to -$2.3 million in 2026.
• According to Business Quant data, EBIT over the past three periods registered -$2.3 million, -$1.7 million, and -$1.6 million for Q2 2026, Q1 2026, and Q4 2025 respectively.